发明名称 NOVEL FUSED INDAN DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
摘要 <p>A fused indan derivative represented by general formula (1), a pharmaceutically acceptable salt thereof, and an antitumor drug, wherein ring A represents an optionally substituted benzene or naphtalene ring, or a benzene ring having a lower alkylenedioxy group; ring B represents a benzene ring which may be substituted or has a lower alkylenedioxy group; Y represents -N=CR- or -CR=N-; R represents -NR1R2, -OR3 or an optionally substituted nitrogenous heterocyclic group; R1 and R2 are the same or different from each other and each represents hydrogen, phenyl, an optionally substituted nitrogenous heterocyclic group, or a lower alkyl group which may be substituted by at least one substituent selected from the group consisting of optionally substituted amino, lower alkoxy, phenyl, a nitrogenous heterocyclic group, an amine oxide group substituted by lower alkyl, and hydroxy; and R3 represents lower alkyl which may be substituted by substituted amino, provided the case where R represents an optionally substituted nitrogenous heterocyclic group and rings A and B represent each an unsubstituted benzene ring, is excluded. <CHEM></p>
申请公布号 GR3036795(T3) 申请公布日期 2002.01.31
申请号 GR20010401657T 申请日期 2001.10.04
申请人 TAIHO PHARMACEUTICAL CO., LTD. 发明人 OKAZAKI, SHINJI;ASAO, TETSUJI;WAKIDA, MOTOJI;ISHIDA, KEISUKE;WASHINOSU, MASATO;UTSUGI, TERUHIRO;YAMADA, YUJI
分类号 A61K31/44;A61K31/473;A61P35/00;C07D221/18;C07D401/12;C07D491/04;C07D491/056;C07D521/00;(IPC1-7):C07D221/18;A61K31/47 主分类号 A61K31/44
代理机构 代理人
主权项
地址